Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Follicular Lymphoma Clinical Trials

11 recruiting trials for Follicular Lymphoma. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
11
Total Trials
11
Recruiting Now
1
Phase 3 Trials
10
Sponsors

Recruiting Trials

RECRUITINGPhase 2NCT03314974

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or,...

Sponsor: Masonic Cancer Center, University of MinnesotaEnrolling: 3001 location
RECRUITINGNCT03501576

Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

This clinical trial evaluates the influenza virus vaccination in evaluating human immune response in patients with lymphoma. Evaluating immune response may increase the...

Sponsor: Emory UniversityEnrolling: 2002 locations
RECRUITINGPhase 1NCT04775745

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed...

Sponsor: Newave Pharmaceutical IncEnrolling: 604 locations
RECRUITINGPhase 1NCT06026319

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated...

Sponsor: Marcela V. Maus, M.D.,Ph.D.Enrolling: 241 location
RECRUITINGPhase 2NCT06563596

Epco, Zanu, Ritux for R/R FL or MZL

The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory...

Sponsor: Reid Merryman, MDEnrolling: 453 locations
RECRUITINGPhase 3NCT06911502

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's...

The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's...

Sponsor: CelgeneEnrolling: 40020 locations
RECRUITINGNCT06813573

Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma

The goal of this study is to prospectively follow the level of circulating nucleosomes in patients treated for a non-Hodgkin lymphoma and determine whether it correlates with the...

Sponsor: Gustave Roussy, Cancer Campus, Grand ParisEnrolling: 501 location
RECRUITINGPhase 1NCT05653271

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell...

Sponsor: Acepodia Biotech, Inc.Enrolling: 4213 locations
RECRUITINGNCT06852638

CD70-targeted immunoPET Imaging of Malignant Cancers

This study aims to establish and optimize the cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging method and...

Sponsor: RenJi HospitalEnrolling: 3001 location
RECRUITINGNCT01962636

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases,...

Sponsor: Masonic Cancer Center, University of MinnesotaEnrolling: 2001 location
RECRUITINGNCT06784167

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as...

Sponsor: OHSU Knight Cancer InstituteEnrolling: 451 location